Inflammation and pain have all been successfully treated using nonsteroidal anti-inflammatory drugs. Today's nonsteroidal anti-inflammatory drugs (NSAIDs) are typically taken with restriction due to the gastric intolerance they create. The prodrug approach is quite effective in reducing the side effects caused by NSAIDs. Many nonsteroidal anti-inflammatory drug molecules have been modified in several ways so that they can be less hazardous to the stomach. Using the mutual prodrug concept, the side effects can be minimized by covalently bonding the NSAIDs to the second pharmacologically active carrier. The goal of the current study is to use the coupling approach to create mutual ester prodrugs of NSAIDs (MS and MP) in order to overcome the troubles, they cause, like gastrointestinal toxicity, ulcerogenic side effects, etc. The prodrugs were made by using a better reagent, EDAC 1-Ethyl-3-(3-Dimethylaminopropyl) carbodiimide hydrochloride, because it outperformed DCC (N, N′-Dicyclohexylcarbodiimide) as a coupling agent. The physiochemical properties were determined, and the structures of the synthesized prodrugs were confirmed and analyzed by UV, FT-IR, 1 HNMR, 13 CNMR Spectroscopy and Mass spectrometry.
INTRODUCTION:The clinical importance of NSAIDs is enormous, but there's a robust risk that they might have negative effects on the abdomen. The ability of NSAIDs to restrict the activity of the enzyme cyclooxygenase (COX) involved in prostaglandin H 2 (PGH 2 ) production is correlated with their pharmacological effectiveness 1, 2 . It is generally known that COX has two isoforms, COX-I and COX-II, which are controlled in various ways. In the GIT, COX-I is expressed constitutively in the stomach to provide cytoprotection, and COX-II plays a major role in the biosynthesis of prostaglandin, which is expressed in inflammatory cell 3 .